Abstracts tagged "Lupus and hydroxychloroquine"

Abstract Number: 1601 • 2017 ACR/ARHP Annual Meeting
Hydroxychloroquine Non-Adherence Is Associated with Higher Sledai Scores in a Predominantly Hispanic Population
Alexandra Perel-Winkler¹, Kayla Neville¹, James Miceli¹, Samantha Nguyen¹, Miya Okado¹, Laura Geraldino-Pardilla¹, Teja Kapoor¹, Jon T. Giles² and Anca Askanase¹, ¹Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ²Division of Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY
Background/Purpose: Non-adherence to medication has been shown to impact mortality, morbidity, and health care utilization in SLE and ranges from 40-80% depending on the methods…
Abstract Number: 929 • 2016 ACR/ARHP Annual Meeting
Retinal Examinations Among SLE Patients Newly-Initiating Hydroxychloroquine in a U.S. Medicaid SLE Population, 2000-10
Tzu-Chieh Lin¹, CH Feldman², Hongshu Guan³, Sarah Chen⁴, Medha Barbhaiya¹ and Karen H. Costenbader¹, ¹Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Social and Behavioral Sciences, Harvard T. H. Chan School of Public Health, Boston, MA, ³Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁴Beth Israel Deaconess Medical Center, Boston, MA
Background/Purpose: U.S. Medicaid provides medical benefits to low-income people. Although the Federal government establishes guidelines, each state sets vision benefits. The American Academy of Ophthalmology…
Abstract Number: 2010 • 2016 ACR/ARHP Annual Meeting
Predictive Factors of Adherence to Treatment in an International Prospective Study of Blood Hydroxychloroquine Levels in SLE Patients with Flares
Nathalie Costedoat-Chalumeau¹, Frédéric A. Houssiau², Peter M. Izmirly³, Véronique Le Guern⁴, Sandra V. Navarra⁵, Meenakshi Jolly⁶, Guillermo RUIZ-IRASTORZA⁷, Eric Hachulla⁸, Nancy Agmon-Levin⁹, Yehuda Shoenfeld¹⁰, Francesca Dall'Ara¹¹, Jill P. Buyon¹², Christophe Deligny¹³, Ricard Cervera¹⁴, Estibaliz Lazaro¹⁵, Holy Bezanahary¹⁶, Gabriel Baron¹⁷, Gaëlle Leroux¹⁸, Nathalie Morel⁴, Jean-Francois Viallard¹⁹, Christian Pineau²⁰, Lionel Galicier²¹, Ronald van Vollenhoven²², Angela Tincani²³, Hanh Nguyen²⁴, Guillaume Gondran²⁵, Noel Zahr²⁶, Jacques Pouchot²⁷, Jean Charles Piette²⁸, Michelle Petri²⁹ and David A. Isenberg³⁰, ¹Internal Medicine, Cochin University Hospital, Paris, France, ²Rheumatology, Pôle de Maladies Rhumatismales, Université catholique de Louvain, Brussels, Belgium, ³New York University School of Medicine, New York, NY, ⁴Internal Medicine Department, Cochin Hospital, “René-Descartes Paris V” University, Paris, France, ⁵Rheumatology, University of Santo Tomas Hospital, Manila, Philippines, ⁶Rush, Chicago, IL, ⁷Cruces University Hospital, Barakaldo, Spain, ⁸Internal Medicine, Lille University Hospital, Lille, France, ⁹Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel Aviv, Israel, ¹⁰Zabludowicz Center for Autoimmune Diseases, Chaim Sheba Medical Center, Tel Hashomer, Israel Incumbent of the Laura Schwarz-Kipp Chair for Research of Autoimmune Diseases, Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel, ¹¹University of Pavia, Pavia, Italy, ¹²Medicine, New York University School of Medicine, New York, NY, ¹³Zobda Quitman Hospital, Rheumatology and Internal Medicine, Fort de France, Martinique, ¹⁴Department of Autoimmune Diseases, Hospital Clinic, Barcelona, Spain, ¹⁵Centre François Magendie, CHU de Bordeaux, Pessac, France, ¹⁶Internal Medicine, University Hospital of Limoges, Limoges, France, ¹⁷Hôpital Hôtel Dieu, Paris, France, ¹⁸Internal Medicine, Pitié-Salpêtrière University Hospital, Paris, France, ¹⁹Internal Medecine, Haut Lévèque Hospital, Bordeaux, France, ²⁰Rheumatology, MUHC, Montreal, QC, Canada, ²¹Clinical Immunology, St Louis Hospital, Paris, France, ²²Amsterdam Rheumatology Center, Amsterdam, Netherlands, ²³Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ²⁴Centre of Rheumatology. Medicine., University College of London Hospital, london, United Kingdom, ²⁵Internal Medicine Department, Limoges, France, ²⁶Pitié Salpêtrière, Pharmacological, Pitié Salpêtrière, Paris, France, ²⁷Internal Medicine Department, European Hospital Georges Pompidou, Paris, France, ²⁸Internal Medicine Department, University Hospital “Pitié-Salpêtrière”, “Pierre et Marie Curie Paris VI” University, Paris, France, ²⁹Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD, ³⁰Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom
Background/Purpose: Non-adherence to treatment, a major cause of continued lupus activity and flares, may be difficult to recognize. In this international prospective study, we evaluated…
Abstract Number: 744 • 2016 ACR/ARHP Annual Meeting
Factors Related to Blood Hydroxychloroquine Concentration in Patients with Systemic Lupus Erythematosus
Ji Yeon Lee¹, Jennifer Lee², Seung-Ki Kwok³, Ji Hyeon Ju⁴, Kyung-Su Park⁵ and Sung-Hwan Park⁴, ¹International Healthcare Center, Seoul St Mary's Hosiptal, Seoul, Korea, Republic of, ²Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of, ³[email protected], Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ⁴Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ⁵Internal Medicine, St. Vincent's Hospital, The Catholic University of Korea, Suwon, Korea, The Republic of
Background/Purpose: To identify factors associated with blood concentrations of hydroxychloroquine (HCQ) and its major metabolite, N-desethylhydroxychloroquine (DHCQ), in patients with systemic lupus erythematosus (SLE) receiving…
Abstract Number: 779 • 2016 ACR/ARHP Annual Meeting
Factors Determining Hydroxychloroquine Serum Levels in a Cohort of Chinese Patients with Systemic Lupus Erythematosus
Chi Chiu Mok¹, Ling Yin Ho² and Paul Jannetto³, ¹Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, ²Dept of Medicine, Tuen Mun Hospital, Hong Kong SAR, Hong Kong, ³Director, Toxicology and Drug Monitoring Laboratory, Mayo Clinic, Rochester, MN
Background/Purpose: To study the factors determining the hydroxychloroquine (HCQ) serum concentration in a cohort of Chinese patients with systemic lupus erythematosus (SLE). Methods: Consecutive patients…
Abstract Number: 1806 • 2015 ACR/ARHP Annual Meeting
Hydroxychloroquine Serum Levels and Flares of Systemic Lupus Erythematosus: A Longitudinal Cohort Analysis
Chi Chiu Mok¹, Hannah Penn², Sau Mei Tse¹, Loralie Langman², Kar Li Chan¹ and Paul Jannetto³, ¹Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, ²Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, ³Director, Toxicology and Drug Monitoring Laboratory, Mayo Clinic, Rochester, MN
Background/Purpose: To study the relationship between the serum hydroxychloroquine (HCQ) concentration and flares of systemic lupus erythematosus (SLE) in a longitudinal cohort of Chinese patients.Methods:…
Abstract Number: 679 • 2014 ACR/ARHP Annual Meeting
Hydroxychloroquine Dosing and Disease Activity in a Large Multi-Racial Lupus Cohort
Jennifer M. Grossman¹, Megan E. B. Clowse², Peter M. Izmirly³, Diane L. Kamen⁴, Alana B. Levine⁵, Meggan Mackey⁶, W. Joseph McCune⁷, Jerry McGwin⁸, David S. Pisetsky⁹, Tammy Utset¹⁰ and Jinoos Yazdany¹¹, ¹Division of Rheumatology, Department of Medicine, UCLA David Geffen School of Medicine, Los Angeles, CA, ²Rheumatology, Duke University Medical Center, Durham, NC, ³Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁴Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC, ⁵Rheumatology, Hospital for Special Surgery, New York, NY, ⁶Autoimmune & Musculoskeletal Disease, The Feinstein Institute, Mahasset, NY, ⁷Int Med/ Rheum, University of Michigan, Ann Arbor, MI, ⁸Biostats, UAB, Birmingham, AL, ⁹Duke University Medical Center, Durham, NC, ¹⁰Internal Medicine/Rheumatology, UC Pritzker Schl of Medicine, Chicago, IL, ¹¹Medicine, University of California, San Francisco, San Francisco, CA
Background/Purpose: Treatment with hydroxychloroquine (HCQ) is recommended for all patients with lupus nephritis to prevent further damage and reduce disease manifestations. Some studies suggest…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.